In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis

International Journal of Antimicrobial Agents

Volumn 30, Issue 2, 2007, Pages 157-161

  Carrillo Munoz A J ^a   Giusiano, G ^b   Guarro, J ^c   Quindos G ^d   Guardia, C ^e   del Valle, O ^f   Rodriguez V ^f   Estivill, D ^g   Cardenes C D ^a  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^c UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e CAP Dr Robert   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g Althaia   (Spain)

Author keywords

Antifungal; Fluconazole; Onychomycosis; Scopulariopsis; Trichophyton; Voriconazole

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CULTURE MEDIUM; DERMATOPHYTE; DILUTION; FUNGUS CULTURE; FUNGUS ISOLATION; FUSARIUM; MICRODILUTION METHOD; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SCOPULARIOPSIS BREVICAULIS; SCYTALIDIUM DIMIDIATUM;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; ONYCHOMYCOSIS; PYRIMIDINES; TRIAZOLES;

EID: 34250870200     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.04.004     Document Type: Article

References (23)

1. Arrese J.E., Valverde J.C., and Pierard G.E. Revisiting the epidemiology of onychomycoses. Rev Iberoam Micol 22 (2005) 163-166 [in Spanish]
2. Purim K.S., Bordignon G.P., and Queiroz-Telles F. Fungal infection of the feet in soccer players and non-athlete individuals. Rev Iberoam Micol 22 (2005) 34-38
3. Borman A.M., Campbell C.K., Fraser M., and Johnson E.M. Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades. Med Mycol 45 (2007) 131-141
4. Santos D.A., and Hamdan J.S. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 44 (2006) 357-362
5. Romano C., Papini M., Ghilardi A., and Gianni C. Onychomycosis in children: a survey of 46 cases. Mycoses 48 (2005) 430-437
6. del Palacio A., Garau M., González-Escalada A., and Calvo M.T. Trends in the treatment of dermatophytoses. In: Kushwaha R.K.S., and Guarro J. (Eds). Biology of dermatophytes and other keratinophilic fungi (2000), Revista Iberoamericana de Micologia, Bilbao, Spain 148-158
7. Pemán J., Salavert M., Cantón E., et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag 2 (2006) 1-30
8. ®). Rev Iberoam Micol 22 (2005) 108-111
9. Carrillo-Muñoz A.J., Quindós G., and López-Ribot J.L. Current developments in antifungal agents. Curr Med Chem Anti Infect Agents 3 (2004) 297-323
10. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. Wayne, PA: NCCLS; 2002.
11. Fernández-Torres B., Cabañes F.J., Abarca L., Carrillo-Muñoz A.J., Inza I., and Guarro J. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 40 (2002) 3999-4003
12. Fernández-Torres B., Carrillo-Muñoz A.J., Martín E., et al. In vitro activities of 10 antifungal drugs against 508 strains of dermatophytes. Antimicrob Agents Chemother 45 (2001) 2524-2528
13. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol 145 (2001) 21-26
14. Ghannoum M., Isham N., and Sheehan D. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial. J Clin Microbiol 44 (2006) 2579-2580
15. Perea S., Fothergill A.W., Sutton D.A., and Rinaldi M.G. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 39 (2001) 385-388
16. Serrano-Martino M.C., Chavez-Caballero M., Valverde-Conde A., Claro R.M., Pemán J., and Martín-Mazuelos E. In vitro activity of voriconazole and three other antifungal agents against dermatophytes. Enferm Infecc Microbiol Clin 21 (2003) 484-487 [in Spanish]
17. Krishnan S., Manavathu E.K., and Chandrasekar P.H. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 55 (2005) 914-920
18. Korting H.C., Ollert M., and Abeck D. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group. Antimicrob Agents Chemother 39 (1995) 1206-1208
19. Aguilar C., Pujol I., and Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother 43 (1999) 1520-1522
20. Johnson E.M., Szekely A., and Warnock D.W. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mould pathogens. Antimicrob Agents Chemother 43 (1999) 1260-1263
21. Wildfeuer A., Seidl H.P., Paule I., and Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41 (1998) 309-319
22. Ryder N.S. Activity of terbinafine against serious fungal pathogens. Mycoses 42 (1999) 115-119
23. Cuenca-Estrella M., Gomez-Lopez A., Buitrago M.J., Mellado E., Garcia-Effron G., and Rodriguez-Tudela J.L. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother 50 (2006) 2248-2250